FREE ELECTRONIC LIBRARY - Dissertations, online materials

Pages:   || 2 | 3 | 4 | 5 |   ...   | 9 |

«Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 December 2013 Statement of Funding and Purpose This report incorporates data ...»

-- [ Page 1 ] --

AHRQ Healthcare Horizon Scanning System – Potential

High-Impact Interventions Report

Priority Area 08: Functional Limitations and Disability

Prepared for:

Agency for Healthcare Research and Quality

U.S. Department of Health and Human Services

540 Gaither Road

Rockville, MD 20850


Contract No. HHSA290201000006C

Prepared by:

ECRI Institute

5200 Butler Pike

Plymouth Meeting, PA 19462

December 2013

Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

This report’s content should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual topic profiles are developed for technologies and programs that appear to be close to diffusion into practice in the United States.

Those reports are sent to various experts with clinical, health systems, health administration, and/or research backgrounds for comment and opinions about potential for impact. The comments and opinions received are then considered and synthesized by ECRI Institute to identify interventions that experts deemed, through the comment process, to have potential for high impact. Please see the methods section for more details about this process. This report is produced twice annually and topics included may change depending on expert comments received on interventions issued for comment during the preceding 6 months.

A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in horizon scanning, assessing the leads for topics, or providing opinions regarding potential impact of interventions.

Disclaimer Regarding 508-Compliance Individuals using assistive technology may not be able to fully access information in this report. For assistance contact info@ahrq.gov.

Financial Disclosure Statement None of the individuals compiling this information has any affiliations or financial involvement that conflicts with the material presented in this report.

Public Domain Notice This document is in the public domain and may be used and reprinted without special permission.

Citation of the source is appreciated.

Suggested citation: ECRI Institute. AHRQ Healthcare Horizon Scanning System Potential HighImpact Interventions: Priority Area 08: Functional Limitations. (Prepared by ECRI Institute under Contract No. HHSA290201000006C.) Rockville, MD: Agency for Healthcare Research and Quality. December 2013. http://effectivehealthcare.ahrq.gov/index.cfm/who-is-involved-in-theeffective-health-care-program1/ahrq-horizon-scanning-system/ i Preface The purpose of the AHRQ Healthcare Horizon Scanning System is to conduct horizon scanning of emerging health care technologies and innovations to better inform patient-centered outcomes research investments at AHRQ through the Effective Health Care Program. The Healthcare Horizon Scanning System provides AHRQ a systematic process to identify and monitor emerging technologies and innovations in health care and to create an inventory of interventions that have the highest potential for impact on clinical care, the health care system, patient outcomes, and costs. It will also be a tool for the public to identify and find information on new health care technologies and interventions. Any investigator or funder of research will be able to use the AHRQ Healthcare Horizon Scanning System to select potential topics for research.

The health care technologies and innovations of interest for horizon scanning are those that have yet to diffuse into or become part of established health care practice. These health care interventions are still in the early stages of development or adoption, except in the case of new applications of already-diffused technologies. Consistent with the definitions of health care interventions provided by the Institute of Medicine and the Federal Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs and biologics, medical devices, screening and diagnostic tests, procedures, services and programs, and care delivery.

Horizon scanning involves two processes. The first is identifying and monitoring new and evolving health care interventions that are purported to or may hold potential to diagnose, treat, or otherwise manage a particular condition or to improve care delivery for a variety of conditions. The second is analyzing the relevant health care context in which these new and evolving interventions exist to understand their potential impact on clinical care, the health care system, patient outcomes, and costs. It is NOT the goal of the AHRQ Healthcare Horizon Scanning System to make predictions on the future use and costs of any health care technology. Rather, the reports will help to inform and guide the planning and prioritization of research resources.

We welcome comments on this Potential High-Impact Interventions report. Send comments by mail to the Task Order Officer named in this report to: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to: effectivehealthcare@ahrq.hhs.gov.

–  –  –

Elise Berliner, Ph.D.

Task Order Officer Center for Outcomes and Evidence Agency for Healthcare Research and Quality ii


Executive Summary





Central Nervous System Disorder Intervention

Dimethyl Fumarate (Tecfidera) for Treatment of Relapsing-Remitting Multiple Sclerosis............ 2 Genetic Disorder Intervention

Eliglustat Tartrate for Treatment of Gaucher’s Disease

Renal-Protection Intervention

RenalGuard for Prevention of Contrast-Induced Nephropathy

Sensory Disorder Interventions

Corneal Collagen Cross-Linking (VibeX Riboflavin/KXL System) for Treatment of Progressive Keratoconus

High-intensity Focused Ultrasound (EyeOP1 HIFU-system) for Treatment-Refractory Glaucoma

Ocriplasmin (Jetrea) Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Pediatric Vision Scanner Screening for Strabismus and Amblyopia

Retinal Prosthesis System (Argus II) for Treatment of Retinitis Pigmentosa

Spinal Cord Injury Intervention

Wearable Battery-powered Exoskeletons (ReWalk and Ekso Systems) To Enable Walking After Spinal Cord Injury


Figures Figure 1. Overall high-impact potential: dimethyl fumarate (Tecfidera) for treatment of relapsing forms of multiple sclerosis

Figure 2. Overall high-impact potential: eliglustat tartrate for treatment of Gaucher’s disease.

...... 7 Figure 3. Overall high-impact potential: RenalGuard for prevention of contrast-induced nephropathy

Figure 4. Overall high-impact potential: corneal collagen cross-linking (VibeX/KXL System) for treatment of progressive keratoconus

iii Figure 5. Overall high-impact potential: high-intensity focused ultrasound (EyeOP1 HIFUsystem) for treatment-refractory glaucoma

Figure 6. Overall high-impact potential: ocriplasmin (Jetrea) treatment for symptomatic vitreomacular adhesion including macular hole

Figure 7. Overall high-impact potential: Pediatric Vision Scanner screening for strabismus and amblyopia

Figure 8. Overall high-impact potential: retinal prosthesis system (Argus II) for treatment of retinitis pigmentosa

Figure 9. Overall high-impact potential: wearable powered exoskeletons (ReWalk and Ekso Systems) to enable walking after spinal cord injury

iv Executive Summary Background Horizon scanning is an activity undertaken to identify technological and system innovations that could have important impacts or bring about paradigm shifts. In the health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals, medical devices, diagnostic tests and procedures, therapeutic interventions, rehabilitative interventions, behavioral health interventions, and public health and health promotion activities. In early 2010, the Agency for Healthcare Research and Quality (AHRQ) identified the need to establish a national Healthcare Horizon Scanning System to generate information to inform comparative-effectiveness research investments by AHRQ and other interested entities. AHRQ makes those investments in 14 priority areas. For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures, treatments, screening and diagnostics, therapeutics, surgery, programs, and care delivery innovations that address unmet needs. Thus, we refer to topics identified and tracked in the AHRQ Healthcare Horizon Scanning System generically as “interventions.” The AHRQ Healthcare Horizon Scanning System implementation of a systematic horizon scanning protocol (developed between September 1 and November 30, 2010) began on December 1, 2010. The system is intended to identify interventions that purport to address an unmet need and are up to 3 years out on the horizon and then to follow them up to 2 years after initial entry into the health care system.

Since that implementation, review of more than 16,200 leads about potential topics has resulted in identification and tracking of about 1,900 topics across the 14 AHRQ priority areas and 1 crosscutting area; about 500 topics are being actively tracked in the system.

Methods As part of the Healthcare Horizon Scanning System activity, a report on interventions deemed as having potential for high impact on some aspect of health care or the health care system (e.g., patient outcomes, utilization, infrastructure, costs) is aggregated twice a year. Topics eligible for inclusion are those interventions expected to be within 0–3 years of potential diffusion (e.g., in phase III trials or for which some preliminary efficacy data in the target population are available) in the United States or that have just begun diffusing and that have completed an expert feedback loop.

The determination of impact is made using a systematic process that involves compiling information on topics and issuing topic drafts to a small group of various experts (selected topic by topic) to gather their opinions and impressions about potential impact. Those impressions are used to determine potential impact. Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the same class are read separately), and then topics in the same class of a device, drug, or biologic are aggregated for discussion and impact assessment at a class level for this report. The process uses a topic-specific structured form with text boxes for comments and a scoring system (1 minimal to 4 high) for potential impact in seven parameters. Participants are required to respond to all parameters.

The scores and opinions are then synthesized to discern those topics deemed by experts to have potential for high impact in one or more of the parameters. Experts are drawn from an expanding database ECRI Institute maintains of approximately 350 experts nationwide who were invited and agreed to participate. The experts comprise a range of generalists and specialists in the health care sector whose experience reflects clinical practice, clinical research, health care delivery, health business, health technology assessment, or health facility administration perspectives. Each expert uses the structured form to also disclose any potential intellectual or financial conflicts of interest ES-1 (COIs). Perspectives of an expert with a COI are balanced by perspectives of experts without COIs.

No more than two experts with a possible COI are considered out of a total of the seven or eight experts who are sought to provide comment for each topic. Experts are identified in the system by the perspective they bring (e.g., clinical, research, health systems, health business, health administration, health policy).

The topics included in this report had scores and/or supporting rationales at or above the overall average for all topics in this priority area that received comments by experts. Of key importance is that topic scores alone are not the sole criterion for inclusion—experts’ rationales are the main drivers for the designation of potentially high impact. We then associated topics that emerged as having potentially high impact with a further subcategorization of “lower,” “moderate,” or “higher” within the high-impact-potential range. As the Healthcare Horizon Scanning System grows in number of topics on which expert opinions are received and as the development status of the interventions changes, the list of topics designated as having potentially high impact is expected to change over time. This report is being generated twice a year.

For additional details on methods, please refer to the full AHRQ Healthcare Horizon Scanning System Protocol and Operations Manual published on AHRQ’s Effective Health Care Web site.

Results The table below lists the 15 topics for which (1) preliminary phase III data for drugs were available or phase II data for devices or off-label uses were available; (2) information was compiled and sent for expert comment before October 27, 2013, in this priority area; and (3) we received six to eight sets of comments from experts between April 9, 2012, and October 29, 2013. (Seventyseven topics in this priority area were being tracked in the system as of October 29, 2013.) We present summaries on nine topics (indicated below by an asterisk) that emerged as having highimpact potential on the basis of experts’ comments. The material in this Executive Summary and the report is organized alphabetically by disease state and then by intervention. Readers are encouraged to read the detailed information on each intervention that follows the Executive Summary.

–  –  –

Pages:   || 2 | 3 | 4 | 5 |   ...   | 9 |

Similar works:

«MEDICINE AND FEMALE MONSTROSITY IN NEO-VICTORIAN FICTION: BELINDA STARLING’S THE JOURNAL OF DORA DAMAGE (2007) Lea Heiberg Madsen Universidad de Málaga l.heiberg-madsen@uma.es Victorian medical advances, along with Darwinian science, triggered an increasingly medicalised understanding of Human, which pervaded all spheres of 19th century culture and came to play a crucial role in the Victorians’ perceptions of the body and mind. The medico-scientific differentiation between ‘complete’...»

«Evaluation of Three Types of Mental Health Treatment Outcome for Asian American Clients By Garyn K. Tsuru A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Psychology) in The University of Michigan Doctoral Committee: Assistant Professor Phillip D. Akutsu, Co-Chair Professor Christopher Peterson, Co-Chair Associate Professor Ramaswami Mahalingam Associate Professor Michael Spencer ! Garyn K. Tsuru _ All Rights Reserved This dissertation...»

«August 2011 Newsletter of the Parawai Tramping Club P O Box 771, Paraparaumu NB This is a “shortened version of the newsletter – The Club night & Trip List are available separately on the website Editorial I thought tramping was a physical thing about keeping fit and healthy, about tackling physical challenges, about putting your body on the line and pushing through. Maybe it is but as I read through the trip reports and contributions to this newsletter I can’t but wonder if there is...»

«Beth Marks, PhD, RN Curriculum Vitae GENERAL INFORMATION Contact: Rehabilitation Research and Training Center on Aging with Developmental Disabilities (RRTCADD) Department of Disability and Human Development, M/C 626 College of Applied Health Sciences University of Illinois at Chicago 1640 West Roosevelt Road, Room 736 Chicago, Illinois 60608 773-350-4567 (cell) * 312-929-0326 (fax) bmarks1@uic.edu (email); rrtcadd.org; HealthMattersProgram.org; NOND.org EDUCATION University of Illinois at...»

«22 October 2015 EMA/CHMP/SWP/2145/2000 Rev. 1, Corr. 1* Committee for Medicinal Products for Human Use (CHMP) Guideline on non-clinical local tolerance testing of medicinal products Draft agreed by Safety Working Party 20 March 2014 Adopted by CHMP for release for consultation 25 April 2014 Start of public consultation 30 April 2014 End of consultation (deadline for comments) 31 July 2014 Agreed by Safety Working Party 29 September 2015 Adopted by CHMP 22 October 2015 Date for coming into...»


«Better Eyesight Magazine July, 1919 to June, 1930 -132 Monthly Issues By Ophthalmologist William Horatio Bates M.D. Copyright © November 2nd, 1996, March 25th, 2010. ‘Better Eyesight Magazine July, 1919 to June, 1930 132 Monthly Issues Natural Vision Improvement’ by Ophthalmologist William Horatio Bates M. D., Central-Fixation Publishing Co. Introduction by Clark Night, (Mary Iva Oliver), Clearsight Publishing Co.South San Francisco, CA, Worcester & South Boston, MA, USA....»

«SUMMARY RECORD OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH (Section Animal health and welfare) HELD IN BRUSSELS ON 13 JUNE 2003 President: Mrs. Jaana Husu-Kallio for point 11a, Mr. Bernard Van Goethem for the other points All the Member States were present.1. EXCHANGE OF VIEWS OF THE COMMITTEE ON THE EVOLUTION OF ANIMAL DISEASES IN THE COMMUNITY INCLUDING: Avian influenza The Netherlands The Netherlands distributed and presented a report on the AI disease situation. To date,...»

«Gas Permeable Scleral Contact Lens Policy Number: 9.03.25 Last Review: 11/2013 Origination: 11/2011 Next Review: 11/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for gas permeable scleral contact lens when it is determined to be medically necessary because the criteria shown below are met. When Policy Topic is covered Rigid gas permeable scleral lens may be considered medically necessary for patients who have not responded to topical medications or...»

«Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health – Updated July 2013 On July 16, 2012, the Food and Drug Administration (FDA) approved the use of Truvada®1 (TDF/FTC) as pre-exposure prophylaxis (PrEP) for HIV-uninfected individuals at high risk for sexually acquired HIV infection. Clinical trials2 in several populations have demonstrated efficacy of TDF/FTC as PrEP to prevent HIV acquisition in HIV-unifected individuals...»

«ANATOMY A brief outline for non-medical staff involved in clinical audit, injury scaling or trauma audit The TRAUMA Audit & Research NETWORK DEVELOPING EFFECTIVE CARE FOR INJURED PATIENTS THROUGH PROCESS AND OUTCOME ANALYSIS AND DISSEMINATION ANATOMY Acknowledgements • The Sourcebook of Medical Illustration. Edited by P. Cull. Contributors • P Nee, Consultant in Emergency Medicine, Whiston Hospital • M Woodford, National Coordinator, The Trauma Audit and Research Network • N Zoltie,...»

«From the Slaughter House of Blood to Mr Pickwick: Charles Dickens and Medicine Nicholas Cambridge MD, MRCS, FSA, FLS, FRSA Charles Dickens [1812-70] (Fig 1) was a keen observer and an expert on description. One example of this was in a letter Dickens wrote about his father, John Dickens, after his father was seen by Robert Wade (1798-1872), a urological surgeon, for urinary retention. Dickens wrote that: ‘Wade instantly performed (without chloroform) the most terrible operation known in...»

<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.